Antibody-Mediated Rejection After Lung Transplantation

Ramsey R. Hachem

doi:10.1016/B978-0-08-102723-3.00119-0

Antibody-Mediated Rejection After Lung Transplantation

Ramsey R. Hachem

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

An important role for donor-specific antibodies (DSA) to mismatched human leukocyte antigens (HLA) in lung allograft rejection has been recognized since the late 1990s. Early studies identified the development of HLA antibodies as a risk factor for chronic rejection. Recently, antibody-mediated rejection (AMR) has been increasingly recognized as a form of lung allograft rejection, and the International Society for Heart and Lung Transplantation proposed a consensus definition. However, experience with AMR after lung transplantation remains limited, and outcomes are poor with many patients dying of AMR or developing progressive chronic rejection after the diagnosis.

Original language	English
Title of host publication	Encyclopedia of Respiratory Medicine, Second Edition
Publisher	Elsevier
Pages	735-740
Number of pages	6
Volume	5
ISBN (Electronic)	9780081027240
ISBN (Print)	9780081027233
DOIs	https://doi.org/10.1016/B978-0-08-102723-3.00119-0
State	Published - Jan 1 2021

Keywords

Antibody-mediated rejection
Bronchiolitis obliterans syndrome
Chronic lung allograft dysfunction
Donor-specific antibodies
Human leukocyte antigens
Immunosuppression
Lung transplantation
Outcomes
Restrictive allograft syndrome
Survival

Access to Document

10.1016/B978-0-08-102723-3.00119-0

Cite this

@inbook{3650c553f7d34081bd0ea05128f606b5,

title = "Antibody-Mediated Rejection After Lung Transplantation",

abstract = "An important role for donor-specific antibodies (DSA) to mismatched human leukocyte antigens (HLA) in lung allograft rejection has been recognized since the late 1990s. Early studies identified the development of HLA antibodies as a risk factor for chronic rejection. Recently, antibody-mediated rejection (AMR) has been increasingly recognized as a form of lung allograft rejection, and the International Society for Heart and Lung Transplantation proposed a consensus definition. However, experience with AMR after lung transplantation remains limited, and outcomes are poor with many patients dying of AMR or developing progressive chronic rejection after the diagnosis.",

keywords = "Antibody-mediated rejection, Bronchiolitis obliterans syndrome, Chronic lung allograft dysfunction, Donor-specific antibodies, Human leukocyte antigens, Immunosuppression, Lung transplantation, Outcomes, Restrictive allograft syndrome, Survival",

author = "Hachem, {Ramsey R.}",

year = "2021",

month = jan,

day = "1",

doi = "10.1016/B978-0-08-102723-3.00119-0",

language = "English",

isbn = "9780081027233",

volume = "5",

pages = "735--740",

booktitle = "Encyclopedia of Respiratory Medicine, Second Edition",

publisher = "Elsevier",

}

TY - CHAP

T1 - Antibody-Mediated Rejection After Lung Transplantation

AU - Hachem, Ramsey R.

PY - 2021/1/1

Y1 - 2021/1/1

N2 - An important role for donor-specific antibodies (DSA) to mismatched human leukocyte antigens (HLA) in lung allograft rejection has been recognized since the late 1990s. Early studies identified the development of HLA antibodies as a risk factor for chronic rejection. Recently, antibody-mediated rejection (AMR) has been increasingly recognized as a form of lung allograft rejection, and the International Society for Heart and Lung Transplantation proposed a consensus definition. However, experience with AMR after lung transplantation remains limited, and outcomes are poor with many patients dying of AMR or developing progressive chronic rejection after the diagnosis.

AB - An important role for donor-specific antibodies (DSA) to mismatched human leukocyte antigens (HLA) in lung allograft rejection has been recognized since the late 1990s. Early studies identified the development of HLA antibodies as a risk factor for chronic rejection. Recently, antibody-mediated rejection (AMR) has been increasingly recognized as a form of lung allograft rejection, and the International Society for Heart and Lung Transplantation proposed a consensus definition. However, experience with AMR after lung transplantation remains limited, and outcomes are poor with many patients dying of AMR or developing progressive chronic rejection after the diagnosis.

KW - Antibody-mediated rejection

KW - Bronchiolitis obliterans syndrome

KW - Chronic lung allograft dysfunction

KW - Donor-specific antibodies

KW - Human leukocyte antigens

KW - Immunosuppression

KW - Lung transplantation

KW - Outcomes

KW - Restrictive allograft syndrome

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85143098898&partnerID=8YFLogxK

U2 - 10.1016/B978-0-08-102723-3.00119-0

DO - 10.1016/B978-0-08-102723-3.00119-0

M3 - Chapter

AN - SCOPUS:85143098898

SN - 9780081027233

VL - 5

SP - 735

EP - 740

BT - Encyclopedia of Respiratory Medicine, Second Edition

PB - Elsevier

ER -

Antibody-Mediated Rejection After Lung Transplantation

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this